Alexandra MacLean
Chief Executive Officer at AVENUE THERAPEUTICS, INC.
Net worth: - $ as of 2024-03-30
Profile
Alexandra MacLean is currently the Chief Executive Officer & Director at Avenue Therapeutics, Inc. She is also a Director at Access Vascular, Inc. Previously, she worked as an Entrepreneur in Residence at Fortress Biotech, Inc. and as the Head-Licensing & Business Development at Imbrium Therapeutics LP.
Dr. MacLean holds a graduate degree from the University of Cambridge, an undergraduate degree from McGill University, an MBA from the University of Colorado Boulder, and a doctorate from Vagelos College of Physicians & Surgeons.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-01-08 | 0 ( -.--% ) | - $ | 2024-03-30 |
Alexandra MacLean active positions
| Companies | Position | Start |
|---|---|---|
| AVENUE THERAPEUTICS, INC. | Chief Executive Officer | 2022-07-31 |
Access Vascular, Inc.
 Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Director/Board Member | - |
Former positions of Alexandra MacLean
| Companies | Position | End |
|---|---|---|
| FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 2022-06-30 |
Imbrium Therapeutics LP
 Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Corporate Officer/Principal | - |
Training of Alexandra MacLean
| University of Cambridge | Graduate Degree |
| McGill University | Undergraduate Degree |
| University of Colorado Boulder | Masters Business Admin |
| Vagelos College of Physicians & Surgeons | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FORTRESS BIOTECH, INC. | Health Technology |
| AVENUE THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |
- Stock Market
- Insiders
- Alexandra MacLean
